title: [Treatment strategy of Hodgkin lymphoma].
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Nagai
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D000079963:Brentuximab Vedotin; D002330:Carmustine / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000145:classification / Q000000981:diagnostic imaging / Q000235:genetics / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage; D008466:Mechlorethamine / Q000008:administration & dosage; D008558:Melphalan / Q000008:administration & dosage; D058990:Molecular Targeted Therapy; D009364:Neoplasm Recurrence, Local; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D000069283:Rituximab; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018796:Immunoconjugates; D003561:Cytarabine; D001761:Bleomycin; D011344:Procarbazine; D000069283:Rituximab; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D003606:Dacarbazine; D003907:Dexamethasone; D000079963:Brentuximab Vedotin; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone